POY_1170x120_8-12-19

benzodiazepines

FDA labeling changes target Rx misuse

FDA labeling changes target Rx misuse

SILVER SPRING, Md. — Citing dangers from combined use, the Food and Drug Administration is requiring classwide changes to labeling for opioid analgesics, prescription opioid cough products and benzodiazepines, a group of central nervous system depressant drugs. The FDA said Wednesday that the changes mandate boxed warnings — the agency’s strongest warning — and patient